Revvity (RVTY) 10-K risk factor changes: FY2025 vs FY2024

[added: Our quarterly revenue and results] of operations are highly dependent on the volume and timing of orders received during the quarter.

Environmental events and political changes, including trade barriers and tariffs, [added: such as the recent tariffs announced or imposed on U.S. trading partners] and [added: retaliatory measures threatened or imposed in response, and] war or other conflicts, such as the current [removed: conflicts] [added: conflict] in [removed: Ukraine and the Middle East,] [added: Ukraine,] some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.

If we fail to accurately foresee our customers’ needs and future activities, we may invest heavily in research and development of [added: products that do not lead to significant revenue.]

- changes in trade policy applicable to the regions in which we do business, [added: including changes in U.S. trade policies or the imposition of higher tariffs on products being shipped into and from the U.S.,]

- differing tax laws and changes in those laws (including the enactment by countries of the Organization for Economic Cooperation and Development (OECD) Base Erosion and Profit Shifting Pillar Two, which would impose a minimum corporate income tax rate of [added: at] least [removed: 15%),] [added: 15%, subject to certain safe harbors),] or changes in the countries in which we are subject to taxation,

In addition, global health crises or pandemics, [removed: changes in trade policy,] [added: actual or threatened tariffs,] wars, conflicts, or other changes in a country’s or region’s political or economic conditions, could have a significant adverse effect on our supply chain.

[added: As a result of these rules, we may incur] additional costs in complying with the disclosure requirements and in satisfying those customers who require that the components used in our products be certified as conflict-free, and the potential lack of availability of these materials at competitive prices could increase our production costs.

As of December [removed: 29, 2024,] [added: 28, 2025,] our total assets included [removed: $9.1] [added: $9.0] billion of net intangible assets.

Adverse changes in our business, adverse changes in the [added: key valuation] assumptions used to determine the fair value of our reporting units, or the failure to grow our Life Sciences and Diagnostics [removed: segments may] [added: segments, could] result in [added: an] impairment of our intangible assets, which could adversely affect our results of operations.

The expiration of our previously issued patents may cause us to lose a competitive advantage in certain of the products and [removed: services we provide.]

The legislative and regulatory landscape for privacy and data protection continues to [added: evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business.]

Our sales originating outside the United States represented the majority of our total revenue in fiscal year [removed: 2024.][added: 2025.]

- trade protection measures including embargoes, sanctions and tariffs, [removed: such] as [added: well as] the sanctions and other restrictions implemented by the United States and other governments on the Russian Federation and related parties in connection with the conflict in Ukraine,

Our failure to comply with any of the restrictions in our [added: new] senior unsecured revolving credit [removed: facility,] [added: facility that we entered into in January 2025,] the 2026 Notes, the 2028 Notes, the 2029 Notes, the March 2031 Notes, the September 2031 [removed: Notes,] [added: Notes and] the 2051 Notes, [removed: including our new senior unsecured revolving credit facility that was entered into in January 2025,] or any future indebtedness may result in an event of default under those debt instruments, which [added: could permit acceleration of the debt under those debt instruments, and require us to prepay that debt before its scheduled due date under certain circumstances.]

- changes to economic conditions arising from global health crises and pandemics, climate change, [added: trade policy] or from wars or conflicts.

On October [removed: 24, 2024,] [added: 23, 2025,] we announced that our Board of Directors (our “Board”) had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year [removed: 2024] [added: 2025] that was paid in February [removed: 2025.][added: 2026.]

On January [removed: 23, 2025,] [added: 26, 2026,] we announced that our Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year [removed: 2025] [added: 2026] that will be payable in May [removed: 2025.][added: 2026.]

Recently announced and proposed changes in U.S. funding and regulations have created a more cautious spending environment for our customers and could cause them to become more conservative with both instrumentation and consumable purchases due to funding and regulatory uncertainty.

Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.

We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business.

The development and deployment of AI presents both risks and opportunities, and the implementation process could adversely impact the operations of our business as a whole.

AI algorithms utilized in the deployment may be flawed or based on datasets that are biased or insufficient, and do not adequately take into account the underlying nature of our business.

Failure to adequately train our employees during the deployment of AI could adversely impact our business or result in delays or errors in our offerings.

Our competitiveness could also be negatively impacted by our failure to timely develop or deploy AI in our products and services, particularly if our competitors are successful in AI advancements in their products and services.

The development of AI technology will require significant investment in resources and human capital and could increase our costs.

There is uncertainty related to the legal and regulatory landscape surrounding rapidly evolving AI technologies, particularly in the areas of cybersecurity, intellectual property, and privacy and data protection.

Failure to comply or appropriately respond to this developing landscape may result in increased legal liability, adverse regulatory action, or reputational damage.

services we provide.

Increasing uncertainty in the United States regarding regulation in the healthcare space could subject our business to new or modified regulations.

We cannot predict the scope, timing, or impact of threatened U.S. tariffs on imports, the extent to which other countries may impose retaliatory trade restrictions, or the terms of future trade policy changes.

Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market.

While we have implemented mitigation strategies including manufacturing optimization, supplier collaboration, pricing adjustments, and temporary cost measures, these actions may not fully offset the impact of existing or future tariffs.

Additional tariffs or trade restrictions may materially and adversely affect our results of operations, financial condition, and competitive position.

Our quarterly revenue and results

products that do not lead to significant revenue.

As a result of these rules, we may incur

evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business.

We believe that our business will continue to be subject to increasing regulation as the federal government continues to strengthen its position on healthcare matters, the scope and effect of which we cannot predict.

could permit acceleration of the debt under those debt instruments, and require us to prepay that debt before its scheduled due date under certain circumstances.

Each of the fiscal years ended December [added: 28, 2025 (“fiscal year 2025”), December] 29, 2024 (“fiscal year [removed: 2024”),] [added: 2024”) and] December 31, 2023 (“fiscal year 2023”) [removed: and January 1, 2023 (“fiscal year 2022”)] included 52 weeks.

The fiscal year ending [removed: December 28, 2025] [added: January 3, 2027] (“fiscal year [removed: 2025”)] [added: 2026”)] will include [removed: 52] [added: 53] weeks.

Overview of Fiscal Year [removed: 2024][added: 2025]

Our overall revenue in fiscal year [removed: 2024] [added: 2025] increased by [removed: $4.5] [added: $101.1] million, or [removed: less than 1%,] [added: 4%,] as compared to fiscal year [removed: 2023,] [added: 2024,] reflecting an increase of [removed: $42.7] [added: $68.5] million, or [removed: 3%,] [added: 5%,] in Diagnostics segment revenue and [removed: a decrease] [added: an increase] of [removed: $38.2] [added: $32.5] million, or [removed: 3%,] [added: 2%,] in Life Sciences segment revenue.

The increase in [added: our] Diagnostics segment revenue was [removed: primarily] driven by [removed: increased demand in] [added: both] our [removed: immunodiagnostics] [added: Immunodiagnostics] and [removed: reproductive health businesses, partially offset by a decrease in revenue from our applied genomics business.][added: Reproductive Health businesses.]

Our consolidated gross margin decreased [removed: 16] [added: 104] basis points in fiscal year [removed: 2024,] [added: 2025,] as compared to fiscal year [removed: 2023,] [added: 2024,] primarily due to [removed: an] [added: increased tariffs,] unfavorable [removed: shift] [added: changes] in [removed: product mix] [added: foreign exchange rates,] and [removed: higher] product [removed: costs,] [added: mix shift,] partially offset by [removed: pricing actions and productivity initiatives.][added: the completion of product rebranding efforts in fiscal year 2024.]

Our consolidated operating margin [removed: increased 166] [added: decreased 10] basis points in fiscal year [removed: 2024,] [added: 2025,] as compared to fiscal year [removed: 2023,] [added: 2024,] due to [added: gross margin headwinds, as discussed above, partially offset by] productivity [removed: initiatives] and cost [removed: containment.][added: containment initiatives.]

The analysis in the remainder of this paragraph compares segment revenue for fiscal year [removed: 2024] [added: 2025] as compared to fiscal year [removed: 2023] [added: 2024] and includes the effect of foreign exchange rate fluctuations.

Life Sciences segment revenue was [removed: $1,254.1] [added: $1,431.1] million for fiscal year [removed: 2024,] [added: 2025,] as compared to [removed: $1,292.3] [added: $1,398.6] million for fiscal year [removed: 2023, a decrease] [added: 2024, an increase] of [removed: $38.2] [added: $32.5] million, or [removed: 3%,] [added: 2%,] driven by [removed: a decrease of $47.2 million in instruments revenue and a decrease] [added: an increase] of [removed: $13.5] [added: $35.6] million in [removed: reagents] [added: Software] revenue, partially offset by [removed: an increase] [added: a decrease] of [removed: $22.5] [added: $3.1] million in [removed: software] [added: Life Sciences Solutions] revenue.

Diagnostics segment revenue for fiscal year [removed: 2024] [added: 2025] was [removed: $1,500.9] [added: $1,424.9] million, as compared to [removed: $1,458.2] [added: $1,356.4] million for fiscal year [removed: 2023,] [added: 2024,] an increase of [removed: $42.7] [added: $68.5] million, or [removed: 3%,] [added: 5%,] due to an increase of [removed: $43.7] [added: $41.3] million in [removed: immunodiagnostics] [added: Immunodiagnostics] revenue and an increase of [removed: $22.6 million in reproductive health revenue, partially offset by a decrease of $23.7] [added: $27.2] million in [removed: applied genomics] [added: Reproductive Health] revenue.

Cost of revenue for fiscal year [removed: 2024] [added: 2025] was [removed: $1,217.4] [added: $1,291.7] million, as compared to [removed: $1,210.9] [added: $1,217.4] million for fiscal year [removed: 2023,] [added: 2024,] an increase of approximately [removed: $6.5] [added: $74.3] million, or [removed: 1%.][added: 6%.]

As a percentage of revenue, cost of revenue increased to [removed: 44.2%] [added: 45.2%] in fiscal year [removed: 2024] [added: 2025] from [removed: 44.0%] [added: 44.2%] in fiscal year [removed: 2023,] [added: 2024,] resulting in a decrease in gross margin of approximately [removed: 16] [added: 104] basis points to [removed: 55.8%] [added: 54.8%] in fiscal year [removed: 2024] [added: 2025] from [removed: 56.0%] [added: 55.8%] in fiscal year [removed: 2023] [added: 2024, primarily] due to [removed: an] [added: increased tariffs,] unfavorable [removed: shift] [added: changes] in [removed: product mix] [added: foreign exchange rates] and [removed: higher] product [removed: costs,] [added: mix shift,] partially offset by [removed: pricing actions and productivity initiatives.][added: the completion of product rebranding efforts in fiscal year 2024.]

Stock compensation expense related to awards given to BioLegend employees post-acquisition [removed: added an incremental expense of $0.6 million for fiscal year 2024, as compared to $2.8] [added: was $2.2] million for fiscal year [removed: 2023.][added: 2024.]

Amortization of intangible assets was [removed: $144.4] [added: $141.1] million for fiscal year [removed: 2024,] [added: 2025,] as compared to [removed: $147.6] [added: $144.4] million for fiscal year [removed: 2023.][added: 2024.]

*Selling, [removed: General] [added: General] and Administrative Expenses*

Selling, general and administrative expenses for fiscal year [removed: 2024] [added: 2025] were [removed: $994.1] [added: $991.9] million, as compared to [removed: $1,022.6] [added: $994.1] million for fiscal year [removed: 2023,] [added: 2024,] a decrease of [removed: $28.5] [added: $2.2] million, or [removed: 3%.][added: less than 1%.]

As a percentage of revenue, selling, general and administrative expenses decreased to [removed: 36.1%] [added: 34.7%] in fiscal year [removed: 2024] [added: 2025] from [removed: 37.2%] [added: 36.1%] in fiscal year [removed: 2023.][added: 2024.]

Amortization of intangible assets decreased and was [removed: $215.0] [added: $194.5] million for fiscal year [removed: 2024,] [added: 2025,] as compared to [removed: $217.5] [added: $215.0] million for fiscal year [removed: 2023.][added: 2024.]

[removed: Restructuring] [added: The above decreases were partially offset by an increase in restructuring] and other costs, net, [removed: decreased and were $17.5] [added: which was $55.9] million for fiscal year [removed: 2024,] [added: 2025,] as compared to [removed: $26.6] [added: $17.5] million for fiscal year [removed: 2023.][added: 2024.]

Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, and stock compensation expense related to the awards given to BioLegend employees post-acquisition, [removed: added an incremental expense of] [added: were] $16.3 million for fiscal year [removed: 2024, as compared to $62.0 million for fiscal year 2023.][added: 2024.]

Purchase accounting adjustments decreased expenses by [added: $0.5 million for fiscal year 2025, as compared to] $1.7 million for fiscal year 2024, which primarily consisted of a change in fair value of contingent [removed: consideration, as compared to increasing expenses by $4.3 million for fiscal year 2023.][added: consideration.]

Costs for significant environmental matters [removed: also added an incremental expense of $2.5] [added: decreased expenses by $1.2] million for fiscal year [removed: 2023.][added: 2025.]

Significant litigation matters and settlements [removed: added an incremental expense of $7.8] [added: was $12.2] million for fiscal year [removed: 2024 and were minimal] [added: 2025, as compared to $7.8 million] for fiscal year [removed: 2023.][added: 2024.]

Research and development expenses for fiscal year [removed: 2024] [added: 2025] were [removed: $196.8] [added: $215.8] million, as compared to [removed: $216.6] [added: $196.8] million for fiscal year [removed: 2023, a decrease] [added: 2024, an increase] of [removed: $19.7] [added: $19.0] million, or [removed: 9%.][added: 10%.]

As a percentage of revenue, research and development expenses [removed: decreased] [added: increased] to [removed: 7.1%] [added: 7.6%] in fiscal year [removed: 2024] [added: 2025] from [removed: 7.9%] [added: 7.1%] in fiscal year [removed: 2023.][added: 2024.]

| | | | December [removed: 29, 2024] [added: 28, 2025] | | | | | | December [removed: 31, 2023] [added: 29, 2024] | | | | | | | | | | | | | | |

| Interest income | | | $ | [removed: (73,190)] [added: (31,103)] | | | | | $ | [removed: (72,131)] [added: (73,190)] | | | | | | | | | | | | | |

| Interest expense | | | [removed: 96,278] [added: 92,185] | | | | | | [removed: 98,813] [added: 96,278] | | | | | | | | | | | | | | |

| Change in fair value of investments | | | [removed: (7,958)] [added: 11,456] | | | | | | [removed: 33,921] [added: (7,958)] | | | | | | | | | | | | | | |

| Other components of net periodic pension cost | | | [removed: 8,508] [added: 871] | | | | | | [removed: 19,006] [added: 8,508] | | | | | | | | | | | | | | |

| Foreign exchange losses and other expense, net | | | [removed: 6,977] [added: 14,949] | | | | | | [removed: 37,977] [added: 6,977] | | | | | | | | | | | | | | |

| Total interest and other expense, net | | | $ | [removed: 30,615] [added: 88,358] | | | | | $ | [removed: 117,586] [added: 30,615] | | | | | | | | | | | | | |

Interest expense [removed: decreased] [added: was lower for the fiscal year 2025 as compared to prior year] primarily due to [added: a] lower debt balance as a result of the repayment of senior unsecured notes that matured in September [removed: 2023 and September] 2024.

[removed: The] [added: Our] effective tax rates were [removed: 10.5%] [added: 10.6%] and [removed: 1.9%] [added: 10.5%] for fiscal years [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] respectively.

The variation in our effective tax rate from the statutory [added: tax] rate for fiscal year 2024 was primarily the result of general business tax credits of $17.6 million, a prior year true-up related to the tax on foreign earnings of approximately $9.4 million, and favorability in our U.S. taxation of multinational operations of $28.9 million, which were partially offset by an increase in valuation allowance of $29.8 million.

Fiscal Year [removed: 2023] [added: 2025] Compared to Fiscal Year [removed: 2022][added: 2024]

For a discussion of our results of operations for fiscal year [removed: 2023] [added: 2024] as compared to fiscal year [removed: 2022,] [added: 2023,] see Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations in our annual report on Form 10-K for the fiscal year ended December [removed: 31, 2023] [added: 29, 2024] filed with the Securities and Exchange Commission on February [removed: 27, 2024.][added: 25, 2025.]

[removed: Revenue] [added: Segment operating income] for fiscal year [removed: 2024] [added: 2025] was [removed: $1,254.1] [added: $344.2] million, as compared to [removed: $1,292.3] [added: $353.9] million for fiscal year [removed: 2023,] [added: 2024,] a decrease of [removed: $38.2] [added: $9.8] million, or 3%.

The [removed: decrease] [added: increase] in our Life Sciences segment revenue was driven by [removed: a decrease of $47.2 million in instruments revenue and a decrease] [added: an increase] of [removed: $13.5] [added: $35.6] million in [removed: reagents] [added: Software] revenue, partially offset by [removed: an increase] [added: a decrease] of [removed: $22.5] [added: $3.1] million in [removed: software] [added: Life Sciences Solutions] revenue.

Segment operating income for fiscal year [removed: 2024] [added: 2025] was [removed: $448.0] [added: $458.3] million, as compared to [removed: $489.3] [added: $467.3] million for fiscal year [removed: 2023,] [added: 2024,] a decrease of [removed: $41.3] [added: $9.0] million, or [removed: 8%.][added: 2%.]

The increase in our Life Sciences segment revenue was driven by our Software business.

Stock compensation expense related to awards given to BioLegend employees

post-acquisition added an incremental expense of $0.6 million for fiscal year 2024.

Tariffs enacted and implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million.

Through proactive mitigation efforts, the net impact on gross margin was approximately $20 million.

The majority of this impact affected products manufactured in Europe and sold in the U.S. market.

Our comprehensive mitigation strategy included manufacturing optimization, supplier collaboration, selective pricing adjustments, and targeted temporary cost measures to minimize ongoing financial exposure.

Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, were $3.8 million for fiscal year 2025.

Asset impairment was $22.8 million for fiscal year 2024.

Restructuring and other costs, net in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of our workforce.

Transformation costs were $9.3 million for fiscal year 2025.

Excluding the items noted above, selling, general and administrative expenses increased slightly due to unfavorable changes in foreign exchange rates and investments in digital capabilities and innovation mostly offset by lower long-term incentive compensation costs, cost control and productivity initiatives.

The increase in research and development expenses was primarily driven by unfavorable changes in foreign exchange rates and our investments in new product development.

The decrease in interest income for the fiscal year 2025 as compared to the fiscal year 2024 was primarily due to a decrease in marketable securities and short-term investments.

The variation in our effective tax rate from the statutory rate for fiscal year 2025 was primarily impacted by federal tax credits of $24.0 million, and the net benefits of U.S. international tax regimes of $6.6 million, partially offset by $2.7 million of other items.

Fiscal Year 2025 Compared to Fiscal Year 2024

Revenue for fiscal year 2025 was $1,431.1 million, as compared to $1,398.6 million for fiscal year 2024, an increase of $32.5 million, or 2%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates.

Fiscal Year 2025 Compared to Fiscal Year 2024

Revenue for fiscal year 2025 was $1,424.9 million, as compared to $1,356.4 million for fiscal year 2024, an increase of $68.5 million, or 5%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates.

Segment operating margin decreased 194 basis points to 24.2% in fiscal year 2025, as compared to 26.1% in fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift due to China diagnostic testing policy changes.

For a discussion of our results of operations for fiscal year 2024 as compared to fiscal year 2023, see Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations in our annual report on Form 10-K for the fiscal year ended December 29, 2024 filed with the Securities and Exchange Commission on February 25, 2025.

Fiscal Year 2025 Compared to Fiscal Year 2024

non-cash charges aggregating to $400.2 million, including depreciation and amortization of $427.8 million, and a net cash decrease from changes in working capital of $18.3 million.

For a discussion of our results of operations for fiscal year 2024 as compared to fiscal year 2023, see Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations in our annual report on Form 10-K for the fiscal year ended December 29, 2024 filed with the Securities and Exchange Commission on February 25, 2025.

Our outstanding €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”) will mature in July 2026.

We expect to repay the 2026 Notes with our existing cash on hand or borrowings under our senior unsecured revolving credit facility, or a combination thereof.

facility.

We adopted Accounting Standards Update 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* (“ASU 2023-09”) during fiscal year 2025 and have applied the guidance on a prospective basis, as disclosed in Note 6, *Income Taxes,* in the Notes to Consolidated Financial Statements*.* The adoption did not have a material impact on the financial statements.

*Income taxes:* Significant judgment is required in determining our worldwide provision for income taxes and recording the related tax assets and liabilities.

In the ordinary course of our business, there are operational decisions, transactions, facts and circumstances, and calculations for which the ultimate tax determination is not certain.

Furthermore, our tax positions are periodically subject to challenge by taxing authorities throughout the world.

We provide reserves for potential payments of tax to various tax authorities related to uncertain tax positions.

These reserves are based on a determination of whether a tax benefit taken by the Company in its tax filings is more likely than not to be sustained upon audit based on its technical merits.

The tax benefit recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement.

We regularly review our tax positions in each significant taxing jurisdiction and adjustments are made to our unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in our judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.

Any significant impact as a result of changes in underlying facts, law, tax rates, tax audit, or review could lead to adjustments to one or more of our income tax expense, our effective tax rate, or our cash flow, see Note 6, *Income Taxes,* in the Notes to the Financial Statements.

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases.

This method also requires the recognition of future tax benefits such as net operating loss carryforwards and tax credits, to the extent that realization of such benefits is more likely than not.

We have established valuation allowances against a variety of deferred tax assets, including state net operating loss carryforwards, state income tax credit carryforwards, and certain foreign tax attributes.

During fiscal year 2024, we again delivered differentiated financial performance despite market headwinds, demonstrating the strength of our product portfolio and innovation.

The decrease in Life Sciences segment revenue was driven by a decrease in instruments and reagents revenue due to pharmaceutical and biotechnology market headwinds, partially offset by an increase in software revenue from the timing of contract renewals and new orders.

Revenue for fiscal year 2024 was $2,755.0 million, as compared to $2,750.6 million for fiscal year 2023, an increase of $4.5 million, or less than 1%.

As a result of adjustments to deferred revenue related to certain acquisitions required by business combination accounting rules, we did not recognize $0.8 million of revenue for each of the fiscal years 2024 and 2023 that otherwise would have been recorded by the acquired businesses during each of the respective periods.

The above decreases were partially offset by an increase in asset impairments, which added an incremental expense of $22.8 million for fiscal year 2024.

Excluding the factors above, the net decrease in selling, general and administrative expenses was the result of productivity initiatives and cost containment.

The decrease in research and development expenses was primarily driven by productivity initiatives and cost containment, as well as a decrease in stock compensation expense related to awards given to BioLegend employees post-acquisition, which added an incremental expense of $2.2 million in fiscal year 2024, as compared to $4.3 million for fiscal year 2023.

Interest income increased due to an increase in short-term investments and higher interest rates.

Change in fair value of investments resulted in income of $8.0 million in fiscal year 2024 as compared to expense of $33.9 million in fiscal year 2023 primarily due to the fluctuation in share price of investments in marketable securities, partially offset by fair value changes in notes receivables and other investments.

Other components of net periodic pension cost decreased primarily due to increases in applicable discount rates.

Foreign exchange losses and other expense, net, was lower during fiscal year 2024 as compared to the same period in the prior year primarily due to a foreign exchange loss of $24.0 million that was recognized in fiscal year 2023 related to the cash proceeds from the sale of the Business

that were held offshore.

A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:

| | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | December 29, 2024 | | | | | | December 31, 2023 | | | | | |

| | | | (In thousands) | | | | | | | | | | | |

| Tax at statutory rate | | | $ | 66,386 | | | | | $ | 38,346 | | | | |

| Non-U.S. rate differential, net | | | (13,332) | | | | | | (18,479) | | | | | |

| U.S. taxation of multinational operations | | | (28,879) | | | | | | (4,594) | | | | | |

| State income taxes, net | | | 2,174 | | | | | | (265) | | | | | |

| Impact of rate changes | | | — | | | | | | (12,795) | | | | | |

| Prior year tax matters | | | (9,389) | | | | | | 3,971 | | | | | |

| Effect of stock compensation | | | 2,960 | | | | | | 2,225 | | | | | |

| General business tax credits | | | (17,634) | | | | | | (4,718) | | | | | |

| Transfer pricing matters | | | (2,391) | | | | | | (6,725) | | | | | |

| Change in valuation allowance | | | 29,781 | | | | | | 6,772 | | | | | |

| Effect of foreign repatriations | | | 5,329 | | | | | | (4,737) | | | | | |

| Other, net | | | (1,950) | | | | | | 4,472 | | | | | |

| Total | | | $ | 33,055 | | | | | $ | 3,473 | | | | |

The variation in our effective tax rate from the statutory tax rate for fiscal year 2023 was primarily the result of a favorable ruling from a foreign tax authority of approximately $15.2 million, a prior year true-up related to the tax on foreign earnings of approximately $7.0 million, and a benefit for the state tax rate change on deferred taxes of $12.8 million, which were partially offset by an increase in tax reserves of approximately $33.2 million in respect of unfavorable developments with respect to an uncertain tax position with a foreign tax authority that was partially related to continuing operations.

Segment operating income for fiscal year 2024 was $372.4 million, as compared to $320.1 million for fiscal year 2023, an increase of $52.3 million, or 16%.

Segment operating margin increased 286 basis points in fiscal year 2024, as compared to fiscal year 2023, primarily due to higher volume, productivity initiatives, and cost containment.

Discontinued Operations

On March 13, 2023, we completed the sale (the “Closing”) of certain assets and the equity interests of certain entities constituting our Applied, Food and Enterprise Services businesses (the “Business”) to PerkinElmer Topco, L.P. (formerly known as Polaris Purchaser, L.P.) (the “Purchaser”), a Delaware limited partnership owned by funds managed by affiliates of New Mountain Capital L.L.C. (the “Sponsor”), for an aggregate purchase price of up to $2.45 billion.

We received approximately $2.27 billion in cash proceeds before transaction costs.

At the Closing, we were entitled to an additional $75.0 million in proceeds payable in installments to commence upon our ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the Purchaser (the “Brand Fee”).

The discounted value of the $75.0 million was measured as $65.2 million and was included in the proceeds at Closing.

During the fiscal year 2024, we received $18.8 million of the Brand Fee.

We expect to receive the remaining balance of the Brand Fee in installments in 2025.

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, derivatives, marketable [removed: securities, accounts receivable] [added: securities] and [removed: notes receivables.][added: accounts receivable.]

We believe we had no significant concentrations of credit risk as of December [removed: 29, 2024.][added: 28, 2025.]

We held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling [removed: $409.8] [added: $598.4] million at December [removed: 29, 2024] [added: 28, 2025] and [removed: $412.1] [added: $409.8] million at December [removed: 31, 2023,] [added: 29, 2024,] and the fair value of these foreign currency derivative contracts was insignificant.

Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency [added: translation component of accumulated other comprehensive income (“AOCI”), which offsets translation adjustments on the underlying net assets of foreign subsidiaries.]

As of December [removed: 29, 2024,] [added: 28, 2025,] the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €498.6 million.

The unrealized foreign exchange [removed: (gains)] losses [added: (gains)] recorded in AOCI related to the net investment hedge were [removed: $(31.7)] [added: $67.6] million, [removed: $19.5] [added: $(31.7)] million and [removed: $(34.5)] [added: $19.5] million during the fiscal years [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022,] [added: 2023,] respectively.

See Note [removed: 18,] [added: 19,] *Derivatives and Hedging Activities,* in the Notes to Consolidated Financial Statements for a detailed discussion of our derivative instruments and hedging activities.

As of December [removed: 29, 2024,] [added: 28, 2025,] this computation estimated that there is a 5% chance that the market value of the underlying exposures and the corresponding derivative instruments either increase or decrease due to foreign currency fluctuations by more than [removed: $1.8] [added: $2.7] million.

Specifically, during each of the four quarters ended in fiscal year [removed: 2024,] [added: 2025,] the Value-At-Risk ranged between [removed: $1.0] [added: $1.6] million and [removed: $1.8] [added: $2.7] million, with an average of approximately [removed: $1.5] [added: $2.0] million.

*Interest Rate Risk.* Our debt portfolio is primarily comprised of fixed interest [removed: debt; however, there is $0.5 million of variable rate instruments.][added: debt.]

Our cash and cash equivalents, for which we receive interest at variable rates, were [removed: $1,163.4] [added: $919.9] million at December [removed: 29, 2024.][added: 28, 2025.]

Fluctuations in interest rates can therefore have a direct impact on both our short-term cash flows, as they relate to [removed: interest,] [added: interest income,] and our earnings.

However, no such instruments are outstanding at December [removed: 29, 2024.][added: 28, 2025.]

translation component of accumulated other comprehensive income (“AOCI”), which offsets translation adjustments on the underlying net assets of foreign subsidiaries.

*Interest Rate Risk—Sensitivity*.

Our current earnings exposure for changes in interest rates can be summarized as follows:

i.

Changes in interest rates can cause our interest expense and cash flows to fluctuate to the extent we have borrowing outstanding on our revolving credit facility.

ii.Changes in interest rates can cause our interest income and cash flows to fluctuate.

As of December [removed: 29, 2024,] [added: 28, 2025,] we employed approximately 11,000 employees.

We provide a broad suite of products, [removed: solutions] [added: solutions, software] and services that facilitate optimized workflows, increase productivity, and accelerate every stage of the drug discovery and development pipeline.

[removed: ◦Radiometric detection solutions, including over 750 radiochemicals and instrumentation such as the Tri-Carb® and] [added: ◦The Tri-Carb®,] Quantulus® [removed: GCT] [added: GCT, and plate-based MicroBeta2®] families of liquid scintillation [removed: analyzers, Wizard2TM Gamma counters] [added: analyzers (LSAs),] and [removed: MicroBeta2TM plate based LSA are] [added: Wizard2® Gamma counters,] used for beta, gamma and luminescence counting in microplate and vial formats [removed: utilized in] [added: for] research, environmental and drug discovery applications.

These include PhenoVue® cellular imaging reagents and cell painting kits, [removed: PhenoPlate] [added: PhenoPlate™] (formerly CellCarrier Ultra™) cellular imaging microplates and [removed: GrowDexTM] [added: GrowDex™] hydrogels, fluorophore-conjugated and enzyme-conjugated antibodies, as well as buffers and solutions, such as our Ce3D™ collection of buffers for 3D tissue imaging.

◦A wide range of homogeneous biochemical and cell-based reagents using HTRF®, LANCE® Ultra™, DELFIA®, AlphaLISA®, AlphaLISA® SureFire® Ultra™, AlphaScreen®, [removed: AlphaPlex®] and [added: AlphaPlex®] luminescence assay technologies that can be paired with our microplates, which cover a variety of applications.

◦BioLegend® LEGENDplex™ bead-based reagents, which, in contrast to single analyte assays such as enzyme-linked immunosorbent assays (“ELISAs”), can quantitate up to 14 targets from one small sample volume and [added: be] read on common flow cytometers, and include both desktop and cloud-based analysis software.

◦BioLegend® best-in-class antibodies, recombinant proteins, and related [removed: reagents] [added: reagents, which] are used across multiple applications and research areas, including [added: flow cytometry, microscopy,] proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.

◦Fluorophore-conjugated antibodies [added: that] are used in flow cytometers to characterize protein expression on the surface and in internal compartments of cells.

Notable products are [added: offered under the] Brilliant [removed: Violet™] [added: Violet™, StarBright™ UV,] and the Spark and [removed: FireTM] [added: Fire™] dye [removed: series,] [added: brands,] among others.

◦BioLegend® TotalSeq™ reagents are oligonucleotide-barcoded antibodies that enable [added: high-parameter] protein detection to be combined with traditional RNA or DNA sequencing [removed: experiments with high-parameter protein detection.][added: experiments.]

◦Cell culture and biofunctional assay reagents, including bioactive recombinant proteins, [added: antibodies,] as well as other specialized [removed: reagents] [added: cell culture media] such as Cell-Vive™ T-NK Xeno-Free Serum Substitute (compliant with Good Manufacturing Practice requirements (“GMP”)), and other GMP-produced [removed: recombinant proteins and] reagents.

[removed: ◦BioLegend’s] [added: ◦BioLegend®] catalog of more than [removed: 33,000] [added: 35,000] SKUs, incorporating [removed: antibodies and] a large collection of antibody conjugates and [removed: modifications] [added: modifications,] as well as recombinant proteins, immunoassays, and other supportive reagents and solutions for cell and molecular analysis.

Our Flex-T [removed: products] [added: reagents] can be used to screen the efficacy of antigen peptides for vaccine and drug trials, as well as characterize the dominance of cancer-specific [removed: self-peptides, and more recently, SARS-CoV-2 peptides for COVID-19 research.][added: self-peptides.]

[removed: ◦MimixTM] [added: ◦Mimix™] reference [removed: standards] [added: standards, which] are cell line-derived to mimic patient samples and suitable for next generation sequencing, droplet-digital and real-time PCR as well as Sanger sequencing.

The [removed: platform is] [added: controls are] agnostic for seamless integration into quality control workflows.

◦Expansion of our Western blotting reagents with the addition of the Western Lightning™ One [removed: range,] [added: range reagents,] which [removed: has] [added: have] a pre-mixed one component chemiluminescent HRP substrate for more consistent results.

◦Additional Spark and [removed: FireTM] [added: Fire™] dye-conjugated antibodies, enabling higher-parameter flow cytometry.

◦New fluorescent stains, reagents and secondary antibodies in our [removed: PhenoVueTM] [added: PhenoVue®] cellular imaging reagents portfolio for the detection and analysis of cellular components.

◦GoInVivo™ [added: antibodies,] as well as Ultra-LEAF™ and LEAF™ functional [removed: antibodies] [added: antibodies, which] provide an affordable solution for researchers performing in vivo and ex vivo studies.

◦The Operetta® CLS™ high-content analysis [removed: system] [added: system, which] enables scientists to reveal fine sub-cellular details from everyday assays as well as more complex studies, for example using live cells, 3D and stem cells.

◦The VICTOR [removed: NivoTM] [added: Nivo®] multimode plate reader benchtop system designed for assay development and academic labs, including those using HTRF® and AlphaLISA® assay [removed: technologies.][added: technologies, updated with new software for streamlined data analysis.]

◦The [removed: EnVisionTM] [added: EnVision®] multimode plate reader designed for high-throughput screening laboratories, including those using HTRF®, AlphaScreen® and AlphaLISA® assay technologies.

◦The EnVision [removed: NexusTM] [added: Nexus®] multimode plate [removed: reader, our next generation system] [added: reader] for high-throughput screening with advanced detection technologies for [removed: Alpha,] [added: Alpha™,] TRF, and [removed: Luminescence.][added: Luminescence assays.]

◦In vivo optical imaging platforms [removed: and reagents] for preclinical research, comprised of the IVIS® Spectrum™ [added: system] series for 2D and 3D optical imaging and optionally integrated low-dose CT imaging and the IVIS® Lumina™ [added: system] series for benchtop 2D [removed: imaging, along with IVISbrite® bioluminescent and IVISense® fluorescent imaging agents and imaging reagents.][added: imaging.]

◦The [removed: QuantumTM] [added: Quantum™] GX3 system, which enables low-dose in vivo CT imaging of multiple species and areas of anatomical interest across multiple disease areas by way of high-resolution, tomographic imaging.

◦The high-throughput, microwell Celigo® image cytometry system, the Cellaca® MX high-throughput cell counter, [removed: the Cellaca® PLX image cytometry system,] and the Cellometer® automated cell counters, complemented by consumables and reagents, including reagents and kits for cell counting assays and cell viability, microplates, slides, and counting beads.

[removed: ◦Cellaca®] [added: ◦The Cellaca®] PLX™ image cytometry system combines best-in-class image cytometer hardware, software, validated consumables and optimized reagent kits with validated antibodies from our BioLegend business, and trackable data reporting to enable the simultaneous detection of multiple markers and to streamline cell and gene therapy workflows.

◦The Signals Image Artist™ next-generation image analysis and management platform for drug discovery [removed: research, to help] [added: research helps] scientists process and analyze high-content screening (HCS) and cellular imaging data in a matter of hours [removed: versus] [added: rather than] days or weeks, [removed: so they can make] [added: enabling faster and] more informed [removed: decisions faster.][added: decisions.]

[removed: ◦Signals Research] [added: ◦The Signals Research™] platform equips pharmaceutical scientists with the essential tools to gather, search, mine, analyze and visualize critical data, yielding actionable insights in an automated, predictive, and scalable manner.

[added: It also] empowers scientists and formulators in specialty chemical and food sciences to analyze food, and additives, and create high-performing materials that align with sustainability initiatives, promoting energy efficiency, lower toxicity and a circular economy.

◦The Signals NotebookTM [added: software is a] secure cloud-native electronic lab notebook (ELN) for chemistry, biology, research, and formulations.

[removed: ◦Signals] [added: ◦Since 1985, Signals] ChemDraw® software [removed: providing] [added: provides] solutions with powerful capabilities [removed: and integrations] to help quickly turn ideas and drawings into [removed: publications since 1985.][added: publications.]

[removed: ◦Signals] [added: ◦The Signals] Clinical offering provides a single unified platform to support data access, preparation and analytics, from source to visualization to action.

With unrivaled workflow flexibility to support dynamic collaboration, [added: the] Signals Clinical’s SaaS solution helps accelerate the delivery of urgently needed therapeutics to patients.

◦Signals DLX™ [added: software] powered by [removed: Scitara®] [added: Scitara®, which] establishes seamless, bidirectional connectivity across instruments, LIMS, ELNs and other critical lab systems that previously existed in isolation.

[removed: ◦The] [added: The] latest version [removed: of the Signals Image Artist™ next-generation image analysis and management platform] provides improved 3D cell segmentation and analysis, an AWS S3 cloud deployment option and enhanced cloud security, and compatibility with a broader range of systems, including [removed: the Nexcelom from Revvity Celigo®TM] [added: our Celigo®] image cytometer.

◦Software solutions for [removed: BioLegend®LEGENDplex™ assays and] [added: BioLegend® LEGENDplex™ assays,] multiomics analysis with TotalSeq™ reagents, [added: and CytoScribe™ software for flow cytometry data analysis] that are now part of [removed: BioLegend’s] [added: BioLegend®] data integration offerings.

◦The [removed: Pin-point™] [added: Pin-point®] base editing [removed: platform is] [added: platform,] a CRISPR-Cas9-based technology that allows researchers to make precision base changes in genomic DNA.

This includes [added: the] LentiBOOST® transduction enhancer technology for improved lentiviral transduction efficiency, helping to reduce the cost of goods for cell therapies.

New products introduced or acquired for Life Sciences applications in fiscal year [removed: 2024] [added: 2025, including from our recent acquisition,] include the following:

- Advancing the use of Artificial Intelligence (“AI”) to further strengthen our differentiated offerings and to drive internal operating efficiencies;

- Taking a disciplined approach to capital allocation to support organic investments, pursue mergers and acquisitions and opportunistic share repurchase programs to drive shareholder value.

◦Radiometric detection solutions, including over 750 radiochemicals for use with our liquid and plate-based analyzers, and utilized in research, environmental and drug discovery applications.

TotalSeq™ reagents offer individual antibodies as well as hashtags for sample pooling and large cocktails for the analysis of hundreds of protein markers.

◦BioLegend® MojoSort™ magnetic bead-based reagents for cell isolation with handheld magnets, as well as MojoSort on Columns™, which uses multistands, columns, and separators for cell sorting.

Buffers, magnets, and kits are offered for positive and negative selection.

◦IVISbrite® bioluminescent and IVISense® fluorescent imaging agents and imaging reagents for use on our in vivo optical imaging platforms for preclinical research applications.

◦The BioLegend® Mini ELISA Plate Reader™ streamlines ELISA workflows by providing a fast, compact instrument designed to take up minimal space in a lab.

A single USB cord enables plug-and-play functionality, and 96 detection units scan all 96 wells simultaneously.

Intuitive operation makes it easy to rapidly read a plate and obtain data.

◦The plate::handler™ FLEX automated plate loading solution for our high-content imagers, cell counters and image cytometers.

◦The Zephyr® G3 SPE workstation is a liquid handler that automates the critical steps required in high-throughput Solid Phase Extraction (SPE).

◦Harmony 5.3™ high-content imaging and analysis software supports end-to-end workflows from acquisition through quantitative analysis and results interpretation.

It improves image data handling and search functionality while enabling 2D and 3D cellular phenotyping, live-cell analysis, and standardized assays on our Opera Phenix™ Plus and Operetta CLS™ systems.

◦The CHOSOURCE® expression platform, a robust CHO expression system for the development and manufacturing of biotherapeutics with a track record of over 100 regulatory filings in multiple countries.

◦pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery.

pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs).

They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization.

◦BioLegend® StarBright™ UltraViolet 575, 740, and 795 dyes to expand flow cytometry panel building options for the ultraviolet laser.

New Spark PLUS dyes were released that offer improved brightness and performance, including Spark PLUS V475, B488, and B574.

The Human General Phenotyping (26c) Optimized Panel was also released, providing researchers with pre-selected and optimized choices for antibody/fluorophore combinations.

◦BioLegend® TotalSeq™ cocktails improve ease of use, including Essential Cocktails which examine 100 of the most commonly cited proteins in phenotyping immune cells and Universal V2.0 cocktails, which offer 50 plus new antibody targets over the V1.0 format.

◦The BioLegend® MojoSort™ on Columns™ cell separation system utilizes columns, multistands, and separators, in conjunction with MojoSort magnetic bead-based kits, for positive and negative selection of immune cells from mixed samples or populations.

◦BioLegend® LEGENDplex™ panels for cytokine detection, including Human Inflammation Panel 3, Mouse CD8/NK Panel, Mouse Immune Checkpoint Panel 1, and Mouse Inflammation Panel 2.

◦BioLegend® chemical probes designed for use in flow cytometry and/or microscopy assays, including ATP Red for cell health and metabolism studies; Swift-Click™ Green EdU kits for cell cycle analysis; and LysoFix-GBA™ (Lysosomal GCase) probes for monitoring of GBA1 activity.

◦The BioLegend® Human GPI-APD cocktail for WBC with Control Cells uniquely combines a ready-to-use cocktail to identify rare glycosylphosphatidylinositol (GPI)-deficient cell populations with a patented positive control, offering an important tool for paroxysmal nocturnal hemoglobinuria research.

◦BioLegend® FluoroSpot MAX™ kits combine the principles of ELISpot with fluorescence-based multiplexing, enabling simultaneous detection of two key cytokines at the single-cell level.

Researchers can quantify polyfunctional immune responses with clarity, making it suitable for studies in infectious disease, vaccine development, and autoimmunity.

◦BioLegend® Cell-Vive™ GMP CD3/CD28 Human T Cell Activation Beads and Cell-Vive™ GMP NKp46/CD2 NK Cell activation beads, designed to activate T cells and Natural Killer cells respectively without the need for antigen presenting cells.

◦Mimix™ Geni™ reference standards are highly characterized somatic cancer controls developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative to help clinical diagnostic labs improve the accuracy of cancer diagnostic assays and medical device manufacturers verify their tests and platforms.

◦The AssayMate™ workstation, a benchtop-sized, automated liquid handler designed to optimize a wide range of laboratory applications, integrating technologies such as collision detection, error handling, and real-time run visualization.

◦The VivoJect™ image-guided injection system, designed to work with the Vega™ automated preclinical ultrasound system, and is an innovative, compact injection system that enables researchers to rapidly administer targeted delivery of cells and drug therapies into mice.

◦The VICTOR Kira™ multimode plate reader with advanced monochromator technology for absorbance, fluorescence, and luminescence measurements across multiple wavelengths.

◦The LH 96 automated homogenizer workstation combines intuitive software with on-deck weighing, sample dilution, homogenization, and reformatting.

Its Nuclei AI building block enables reliable nucleus detection without staining, eliminating manual tuning and accelerating image analysis with greater precision.

◦The Living Image™ Synergy AI in vivo imaging software platform enables acquisition, visualization, and quantitative analysis across optical, microCT, ultrasound, and multimodal workflows.

It supports longitudinal studies and standardized reporting to evaluate disease progression and therapeutic response.

◦BioLegend® CytoScribe™ cloud-based software allows researchers to access and analyze data with advanced tools for data visualization, centralized data storage, and seamless collaboration with colleagues.

◦Katalyst D2D® software provides integrated experiment design, planning, execution, and analysis capabilities supporting high-throughput synthesis, process optimization, and preformulation studies.

The platform enables scientists to manage data across the complete design-make-test-analyze cycle and leverage structured data to support AI-driven decision-making.

- Opportunistically utilizing our share repurchase programs to help drive shareholder value.

◦BioLegend®’s MojoSort™ for cell separation that complements our fluorophore-antibody conjugates, used for FACS (Fluorescence-activated Cell Sorting), thus covering most cell separation and cell sorting technologies and applications.

It is complemented by GoInVivo™ as well as Ultra-LEAF™ and LEAF™ functional antibodies providing an affordable solution for researchers performing in vivo and ex vivo studies.

In addition, it also

◦An updated VICTOR Nivo™ multimode plate reader with a new software version for streamlined data analysis.

◦CHOSOURCE™ platform was expanded to include a CHO-K1 ADCC+ expression cell line for development of therapeutic antibodies in oncology, infectious disease and autoimmune conditions.

◦Biolegend launched new dyes to expand flow cytometry panel building options, including PE/Fire™ 744, Spark PLUS UV395™, Spark PLUS™ B550 antibody conjugates and Zombie UV387™ for dead cell analysis.

In addition, the Flexi-Fluor™ portfolio of reagents was created as a made-to-order, rapid alternative to traditional custom products.

◦Oligo-conjugated antibodies for intracellular detection of proteins and cytokines introduced in BioLegend's TotalSeqTM portfolio.

BioLegend also introduced a solution for high-throughput, high-parameter single-cell protein analysis - TotalSeq™ PhenoCyteTM.

PhenoCyteTM provides a streamlined, instrument-free workflow for scalable single-cell immunoprofiling.

- Applied Genomics

◦The Omni Prep 96 Automated Homogenizer Workstation, a fully automated homogenizer enabling true walk-away processing for high-throughput labs.

◦Automation protocols and kits launched for the BioQule™ NGS System, making it an open system that combines automation, reagents, consumables and scripts, enabling walkaway automation to simplify low throughput nucleic acid isolation, NGS library preparation and quantitation.

The chemagic™ 360-D instrument (IVDR) and chemagic™

◦The optimised (IVDR-compliant) “RVTY”"CSF ELISA 2.0" series for facilitated handling and resource savings.

◦The GeneProof-ALPCOTM portfolio for molecular diagnostics.

◦EURORealTime APOE for APOE genotyping to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease.

specified circumstances.

remediation of contaminated soil and groundwater, the regulation of radioactive materials, and the health and safety of our employees.

During fiscal year 2024, our voluntary turnover rate was approximately 9%.

Although we have established accruals for potential losses that we believe are probable and reasonably estimable, in the opinion of our management, based on its review of the information available at this time, the total cost of resolving these contingencies at December [removed: 29, 2024] [added: 28, 2025] should not have a material adverse effect on our consolidated financial statements included in this annual report on Form 10-K.

| | | | For the fiscal year ended December [removed: 29, 2024] [added: 28, 2025] | | |

The aggregate market value of the common stock, $1 par value per share, held by non-affiliates of the registrant on June [removed: 28, 2024,] [added: 27, 2025,] the last business day of the registrant’s most recently completed second fiscal quarter, was [removed: $12,871,238,120] [added: $11,298,522,046] based upon the last reported sale of [removed: $104.86] [added: $97.82] per share of common stock on June [removed: 28, 2024.][added: 27, 2025.]

As of February [removed: 21, 2025,] [added: 20, 2026,] there were outstanding [removed: 120,187,286] [added: 111,799,374] shares of common stock, $1 par value per share.

DOCUMENTS [removed: INCORPORATED] [added: INCORPORATED] BY REFERENCE

Portions of Revvity, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on April [removed: 22, 2025] [added: 28, 2026] are incorporated by reference into Part III of this Form 10-K.

| Item 1. | | | [removed: [Business](#i9b5569a8d050455c84db11039ac6a928_13)] [added: [Business](#if99e0177af0343e1bc626a51b2b27163_13)] | | | [removed: [3](#i9b5569a8d050455c84db11039ac6a928_13)] [added: [3](#if99e0177af0343e1bc626a51b2b27163_13)] | | |

| Item 1A. | | | [Risk [removed: Factors](#i9b5569a8d050455c84db11039ac6a928_16)] [added: Factors](#if99e0177af0343e1bc626a51b2b27163_16)] | | | [removed: [13](#i9b5569a8d050455c84db11039ac6a928_16)] [added: [15](#if99e0177af0343e1bc626a51b2b27163_16)] | | |

| Item 1B. | | | [Unresolved Staff [removed: Comments](#i9b5569a8d050455c84db11039ac6a928_19)] [added: Comments](#if99e0177af0343e1bc626a51b2b27163_19)] | | | [removed: [21](#i9b5569a8d050455c84db11039ac6a928_19)] [added: [23](#if99e0177af0343e1bc626a51b2b27163_19)] | | |

| Item 1C. | | | [Cybersecurity [removed: Disclosures](#i9b5569a8d050455c84db11039ac6a928_22)] [added: Disclosures](#if99e0177af0343e1bc626a51b2b27163_22)] | | | [removed: [22](#i9b5569a8d050455c84db11039ac6a928_22)] [added: [24](#if99e0177af0343e1bc626a51b2b27163_22)] | | |

| Item 2. | | | [removed: [Properties](#i9b5569a8d050455c84db11039ac6a928_25)] [added: [Properties](#if99e0177af0343e1bc626a51b2b27163_25)] | | | [removed: [22](#i9b5569a8d050455c84db11039ac6a928_25)] [added: [24](#if99e0177af0343e1bc626a51b2b27163_25)] | | |

| Item 3. | | | [Legal [removed: Proceedings](#i9b5569a8d050455c84db11039ac6a928_28)] [added: Proceedings](#if99e0177af0343e1bc626a51b2b27163_28)] | | | [removed: [23](#i9b5569a8d050455c84db11039ac6a928_28)] [added: [25](#if99e0177af0343e1bc626a51b2b27163_28)] | | |

| Item 4. | | | [Mine Safety [removed: Disclosures](#i9b5569a8d050455c84db11039ac6a928_31)] [added: Disclosures](#if99e0177af0343e1bc626a51b2b27163_31)] | | | [removed: [23](#i9b5569a8d050455c84db11039ac6a928_31)] [added: [25](#if99e0177af0343e1bc626a51b2b27163_31)] | | |

| Item 5. | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i9b5569a8d050455c84db11039ac6a928_40)] [added: Securities](#if99e0177af0343e1bc626a51b2b27163_40)] | | | [removed: [26](#i9b5569a8d050455c84db11039ac6a928_40)] [added: [28](#if99e0177af0343e1bc626a51b2b27163_40)] | | |

| Item 6. | | | [removed: [\[Reserved\]](#i9b5569a8d050455c84db11039ac6a928_43)] [added: [\[Reserved\]](#if99e0177af0343e1bc626a51b2b27163_43)] | | | [removed: [27](#i9b5569a8d050455c84db11039ac6a928_43)] [added: [29](#if99e0177af0343e1bc626a51b2b27163_43)] | | |

| Item 7. | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i9b5569a8d050455c84db11039ac6a928_49)] [added: Operations](#if99e0177af0343e1bc626a51b2b27163_49)] | | | [removed: [28](#i9b5569a8d050455c84db11039ac6a928_49)] [added: [30](#if99e0177af0343e1bc626a51b2b27163_49)] | | |

| Item 7A. | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#i9b5569a8d050455c84db11039ac6a928_58)] [added: Risk](#if99e0177af0343e1bc626a51b2b27163_58)] | | | [removed: [36](#i9b5569a8d050455c84db11039ac6a928_58)] [added: [36](#if99e0177af0343e1bc626a51b2b27163_58)] | | |

| Item 8. | | | [Financial Statements and Supplementary [removed: Data](#i9b5569a8d050455c84db11039ac6a928_61)] [added: Data](#if99e0177af0343e1bc626a51b2b27163_61)] | | | [removed: [38](#i9b5569a8d050455c84db11039ac6a928_61)] [added: [39](#if99e0177af0343e1bc626a51b2b27163_61)] | | |

| Item 9. | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i9b5569a8d050455c84db11039ac6a928_193)] [added: Disclosure](#if99e0177af0343e1bc626a51b2b27163_187)] | | | [removed: [78](#i9b5569a8d050455c84db11039ac6a928_193)] [added: [82](#if99e0177af0343e1bc626a51b2b27163_187)] | | |

| Item 9A. | | | [Controls and [removed: Procedures](#i9b5569a8d050455c84db11039ac6a928_196)] [added: Procedures](#if99e0177af0343e1bc626a51b2b27163_190)] | | | [removed: [78](#i9b5569a8d050455c84db11039ac6a928_196)] [added: [82](#if99e0177af0343e1bc626a51b2b27163_190)] | | |

| Item 9B. | | | [Other [removed: Information](#i9b5569a8d050455c84db11039ac6a928_199)] [added: Information](#if99e0177af0343e1bc626a51b2b27163_193)] | | | [removed: [81](#i9b5569a8d050455c84db11039ac6a928_199)] [added: [85](#if99e0177af0343e1bc626a51b2b27163_193)] | | |

| Item 9C. | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i9b5569a8d050455c84db11039ac6a928_202)] [added: Inspections](#if99e0177af0343e1bc626a51b2b27163_196)] | | | [removed: [81](#i9b5569a8d050455c84db11039ac6a928_202)] [added: [85](#if99e0177af0343e1bc626a51b2b27163_196)] | | |

| Item 10. | | | [Directors, Executive Officers and Corporate [removed: Governance](#i9b5569a8d050455c84db11039ac6a928_208)] [added: Governance](#if99e0177af0343e1bc626a51b2b27163_202)] | | | [removed: [82](#i9b5569a8d050455c84db11039ac6a928_208)] [added: [86](#if99e0177af0343e1bc626a51b2b27163_202)] | | |

| Item 11. | | | [Executive [removed: Compensation](#i9b5569a8d050455c84db11039ac6a928_211)] [added: Compensation](#if99e0177af0343e1bc626a51b2b27163_205)] | | | [removed: [82](#i9b5569a8d050455c84db11039ac6a928_211)] [added: [86](#if99e0177af0343e1bc626a51b2b27163_205)] | | |

| Item 12. | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i9b5569a8d050455c84db11039ac6a928_214)] [added: Matters](#if99e0177af0343e1bc626a51b2b27163_208)] | | | [removed: [82](#i9b5569a8d050455c84db11039ac6a928_214)] [added: [86](#if99e0177af0343e1bc626a51b2b27163_208)] | | |

| Item 13. | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i9b5569a8d050455c84db11039ac6a928_217)] [added: Independence](#if99e0177af0343e1bc626a51b2b27163_211)] | | | [removed: [82](#i9b5569a8d050455c84db11039ac6a928_217)] [added: [86](#if99e0177af0343e1bc626a51b2b27163_211)] | | |

| Item 14. | | | [Principal Accountant Fees and [removed: Services](#i9b5569a8d050455c84db11039ac6a928_220)] [added: Services](#if99e0177af0343e1bc626a51b2b27163_214)] | | | [removed: [82](#i9b5569a8d050455c84db11039ac6a928_220)] [added: [86](#if99e0177af0343e1bc626a51b2b27163_214)] | | |

| Item 15. | | | [Exhibits and Financial Statement [removed: Schedules](#i9b5569a8d050455c84db11039ac6a928_226)] [added: Schedules](#if99e0177af0343e1bc626a51b2b27163_220)] | | | [removed: [83](#i9b5569a8d050455c84db11039ac6a928_226)] [added: [87](#if99e0177af0343e1bc626a51b2b27163_220)] | | |

| Item 16. | | | [Form 10-K [removed: Summary](#i9b5569a8d050455c84db11039ac6a928_229)] [added: Summary](#if99e0177af0343e1bc626a51b2b27163_223)] | | | [removed: [88](#i9b5569a8d050455c84db11039ac6a928_229)] [added: [92](#if99e0177af0343e1bc626a51b2b27163_223)] | | |

| [Signatures](#if99e0177af0343e1bc626a51b2b27163_226) | | | | | | [92](#if99e0177af0343e1bc626a51b2b27163_226) | | |

| [Signatures](#i9b5569a8d050455c84db11039ac6a928_232) | | | | | | [88](#i9b5569a8d050455c84db11039ac6a928_232) | | |

The program includes processes for the identification, review and assessment of materiality of cyber events, notification of our senior leadership and Board of Directors of such events, and financial reporting [removed: disclosure] [added: disclosures] where applicable.

These measures are conducted [added: at least] annually to ensure our employees remain up-to-date with the latest security practices, complementing our continuously improving processes and systems.

Our Chief Information [added: Security] Officer [added: (“CISO”)] is responsible for developing and implementing our information security program.

[removed: This] [added: To achieve this, the Information Security] team leverages internal IT resources, a managed security service provider, and additional third-party security software and technology services.

When a specific incident has been identified, the Information Security team leverages our Cyber Incident Response Plan in conjunction with established Information Security policies to begin [added: the] assessment of the incident.

Our [removed: Information Security team] [added: CISO] is responsible for escalating incidents which are determined to be higher risk to our Cyber Event Disclosure Committee.

The Cyber Event Disclosure Committee convenes, at least [removed: monthly,] [added: quarterly,] to review recent developments in cybersecurity and in the cybersecurity risk landscape.

Additionally, [added: at least annually,] our Board of Directors is provided with a comprehensive cyber training from our [removed: Chief Information Security Officer at least annually.][added: CISO.]

See Note [removed: 20,] [added: 21,] *Leases,* in the Notes to Consolidated Financial Statements for further discussion of our leases.

Listed below are our executive officers as of February [removed: 25, 2025.][added: 24, 2026.]

| Prahlad Singh | | | | | | President and Chief Executive Officer | | | | | | [removed: 60] [added: 61] | | |

| Maxwell Krakowiak | | | | | | Senior Vice President and Chief Financial Officer | | | | | | [removed: 35] [added: 36] | | |

| Joel S. Goldberg | | | | | | Senior Vice President, Administration, General Counsel and Secretary | | | | | | [removed: 56] [added: 57] | | |

| Miriame Victor | | | | | | Senior Vice President, Chief Commercial Officer | | | | | | [removed: 44] [added: 45] | | |

| Tajinder Vohra | | | | | | Senior Vice President, Global Operations | | | | | | [removed: 59] [added: 60] | | |

| Anita Gonzales | | | | | | Vice [removed: President, Controller] [added: President and Chief Accounting Officer] | | | | | | [removed: 49] [added: 50] | | |

*Prahlad Singh, [removed: 60*.][added: 61*.]

*Maxwell Krakowiak, [removed: 35*.][added: 36*.]

Goldberg*, [removed: *56*.][added: *57*.]

*Miriame Victor, [removed: 44*.][added: 45*.]

*Tajinder Vohra, [removed: 59*.][added: 60*.]

[removed: *Anita Gonzales, 49.*] Mrs. Gonzales [removed: was appointed our Vice President and Controller in May 2023, having] joined Revvity as Senior Director of Integration and Controllership Initiatives in March 2021.

*Anita Gonzales*, 50.

Mrs. Gonzales was appointed our Vice President and Chief Accounting Officer in October 2025, having previously served as our Vice President and Global Controller since May 2023.

As of February [removed: 21, 2025,] [added: 20, 2026,] we had approximately [removed: 2,753] [added: 2,461] holders of record of our common stock.

During the fourth quarter of fiscal year [removed: 2024,] [added: 2025,] we repurchased [removed: 37,443] [added: 2,831] shares of common stock for this purpose at an aggregate cost of [removed: $4.6] [added: $0.3] million.

(2)On [removed: April 27, 2023,] [added: October 24, 2024,] our Board authorized us to repurchase shares of common stock for an aggregate amount up to [removed: $600.0 million] [added: $1.0 billion] under a stock repurchase program (the “Repurchase Program”).

On October [removed: 24, 2024,] [added: 23, 2025,] the Repurchase Program was terminated by our Board and our Board authorized us to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a new stock repurchase program (the “New Repurchase Program”).

The New Repurchase Program will expire on October [removed: 23, 2026,] [added: 22, 2027,] unless terminated earlier by our Board and may be suspended or discontinued at any time.

During fiscal year [removed: 2024,] [added: 2025,] we repurchased [removed: 1,820,296] [added: 7,264,299] shares of common stock under the Repurchase Program for an aggregate cost of [removed: $213.6] [added: $695.4] million.

During the fourth quarter of fiscal year [removed: 2024,] [added: 2025,] we repurchased [removed: 284,985] [added: 515,232] shares of common stock under the Repurchase Program for an aggregate cost of [removed: $34.3] [added: $47.5] million.

During the fourth quarter of fiscal year [removed: 2024,] [added: 2025,] we repurchased [removed: 1,238,755] [added: 1,245,232] shares of common stock under the New Repurchase Program for an aggregate cost of [removed: $142.8] [added: $120.5] million.

As of December [removed: 29, 2024, $857.2] [added: 28, 2025, $879.5] million remained available for aggregate repurchases of shares under the New Repurchase Program.

Our Board of Directors declared a cash dividend of $0.07 per share during the fourth quarter of fiscal year [removed: 2024] [added: 2025] that was paid in February [removed: 2025.][added: 2026.]

Refer to Note [removed: 17,] [added: 18,] *Stockholders' Equity,* in the Notes to Consolidated Financial Statements for further discussion regarding stock repurchases and dividends.

Set forth below is a line graph comparing the cumulative total shareholder return on our common stock against the cumulative total return of the S&P Composite-500 Index and the S&P 500 Life Sciences Tools & Services Industry Index for the five fiscal years from [removed: December 29, 2019] [added: January 3, 2021] to December [removed: 29, 2024.][added: 28, 2025.]

[removed: ][added: ]

| | | | [removed: 12/29/2019] [added: 1/3/2021] | | | | | | [removed: 1/3/2021] [added: 1/2/2022] | | | | | | [removed: 1/2/2022] [added: 1/1/2023] | | | | | | [removed: 1/1/2023] [added: 12/31/2023] | | | | | | [removed: 12/31/2023] [added: 12/29/2024] | | | | | | [removed: 12/29/2024] [added: 12/28/2025] | | |

| S&P 500 Life Sciences Tools & Services Industry Index | | | $ | 100.00 | | | | | $ | [removed: 133.01] [added: 138.73] | | | | | $ | [removed: 184.53] [added: 106.95] | | | | | $ | [removed: 142.26] [added: 103.66] | | | | | $ | [removed: 137.88] [added: 100.04] | | | | | $ | [removed: 133.07] [added: 105.15] | |

| September 29, 2025 - October 26, 2025 | | | 540,865 | | | | | | $ | 92.50 | | | | | 540,504 | | | | | | $ | 997,500,076 | |

| October 27, 2025 - November 23, 2025 | | | 633,116 | | | | | | 93.21 | | | | | | 632,779 | | | | | | 938,516,994 | | |

| November 24, 2025 - December 28, 2025 | | | 589,314 | | | | | | 100.46 | | | | | | 587,181 | | | | | | 879,525,795 | | |

| Activity for quarter ended December 28, 2025 | | | 1,763,295 | | | | | | $ | 95.42 | | | | | 1,760,464 | | | | | | $ | 879,525,795 | |

| Revvity, Inc. | | | $ | 100.00 | | | | | $ | 140.37 | | | | | $ | 98.08 | | | | | $ | 76.63 | | | | | $ | 78.72 | | | | | $ | 68.20 | |

| S&P 500 Index | | | $ | 100.00 | | | | | $ | 128.71 | | | | | $ | 105.40 | | | | | $ | 133.10 | | | | | $ | 166.40 | | | | | $ | 196.16 | |

| September 30, 2024 - October 27, 2024 | | | 351,461 | | | | | | $ | 120.54 | | | | | 30,000 | | | | | | $ | 996,456,502 | |

| October 28, 2024 - November 24, 2024 | | | 537,773 | | | | | | 115.16 | | | | | | 537,705 | | | | | | 934,536,467 | | |

| November 25, 2024 - December 29, 2024 | | | 671,949 | | | | | | 115.23 | | | | | | 671,050 | | | | | | 857,209,712 | | |

| Activity for quarter ended December 29, 2024 | | | 1,561,183 | | | | | | $ | 116.40 | | | | | 1,238,755 | | | | | | $ | 857,209,712 | |

| Revvity, Inc. | | | $ | 100.00 | | | | | $ | 148.27 | | | | | $ | 208.13 | | | | | $ | 145.42 | | | | | $ | 113.62 | | | | | $ | 116.71 | |

| S&P 500 Index | | | $ | 100.00 | | | | | $ | 118.40 | | | | | $ | 152.39 | | | | | $ | 124.79 | | | | | $ | 157.59 | | | | | $ | 197.02 | |

| [Report of Independent Registered Public Accounting [removed: Firm](#i9b5569a8d050455c84db11039ac6a928_64)] [added: Firm](#if99e0177af0343e1bc626a51b2b27163_64)] (PCAOB ID No. 34) | | | [removed: [39](#i9b5569a8d050455c84db11039ac6a928_64)] [added: [40](#if99e0177af0343e1bc626a51b2b27163_64)] | | |

| [Consolidated Statements of Operations for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024](#i9b5569a8d050455c84db11039ac6a928_67)] [added: 28, 2025](#if99e0177af0343e1bc626a51b2b27163_67)] | | | [removed: [40](#i9b5569a8d050455c84db11039ac6a928_67)] [added: [41](#if99e0177af0343e1bc626a51b2b27163_67)] | | |

| [Consolidated Statements of Comprehensive Income for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024](#i9b5569a8d050455c84db11039ac6a928_70)] [added: 28, 2025](#if99e0177af0343e1bc626a51b2b27163_70)] | | | [removed: [41](#i9b5569a8d050455c84db11039ac6a928_70)] [added: [42](#if99e0177af0343e1bc626a51b2b27163_70)] | | |

| [Consolidated Balance Sheets as of December [removed: 29, 2024] [added: 28, 2025] and December [removed: 31, 2023](#i9b5569a8d050455c84db11039ac6a928_73)] [added: 29, 2024](#if99e0177af0343e1bc626a51b2b27163_73)] | | | [removed: [42](#i9b5569a8d050455c84db11039ac6a928_73)] [added: [43](#if99e0177af0343e1bc626a51b2b27163_73)] | | |

| [Consolidated Statements of Stockholders’ Equity for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024](#i9b5569a8d050455c84db11039ac6a928_79)] [added: 28, 2025](#if99e0177af0343e1bc626a51b2b27163_79)] | | | [removed: [43](#i9b5569a8d050455c84db11039ac6a928_79)] [added: [44](#if99e0177af0343e1bc626a51b2b27163_79)] | | |

| [Consolidated Statements of Cash Flows for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024](#i9b5569a8d050455c84db11039ac6a928_82)] [added: 28, 2025](#if99e0177af0343e1bc626a51b2b27163_82)] | | | [removed: [44](#i9b5569a8d050455c84db11039ac6a928_82)] [added: [45](#if99e0177af0343e1bc626a51b2b27163_82)] | | |

| [Notes to Consolidated Financial [removed: Statements](#i9b5569a8d050455c84db11039ac6a928_85)] [added: Statements](#if99e0177af0343e1bc626a51b2b27163_85)] | | | [removed: [46](#i9b5569a8d050455c84db11039ac6a928_85)] [added: [47](#if99e0177af0343e1bc626a51b2b27163_85)] | | |

We have audited the accompanying consolidated balance sheets of Revvity, Inc. and subsidiaries (the “Company”) as of December [removed: 29, 2024] [added: 28, 2025] and December [removed: 31, 2023,] [added: 29, 2024,] the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows, for each of the three years in the period ended December [removed: 29, 2024,] [added: 28, 2025,] and the related notes (collectively referred to as the “financial statements”).

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December [removed: 29, 2024] [added: 28, 2025] and December [removed: 31, 2023,] [added: 29, 2024,] and the results of its operations and its cash flows for each of the three years in the period ended December [removed: 29, 2024,] [added: 28, 2025,] in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December [removed: 29, 2024,] [added: 28, 2025,] based on criteria established in *Internal Control - Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 25, 2025,] [added: 24, 2026,] expressed an unqualified opinion on the Company’s internal control over financial reporting.

Goodwill [removed: of] [added: -] Life Sciences [added: Solutions] Reporting Unit — Refer to Notes 1 and [removed: 11] [added: 12] to the financial statements

As of December [removed: 29, 2024,] [added: 28, 2025,] the Company’s balance of goodwill was [removed: $6.5] [added: $6.6] billion, of which [removed: $4.3] [added: $4.5] billion was allocated to the Life Sciences [added: Solutions] reporting unit.

In connection with the annual impairment assessment as of November [removed: 1, 2024,] [added: 3, 2025,] the Company concluded that the fair value of each reporting unit exceeded the carrying value of each reporting unit and no impairment was recognized.

The fair value of the Life Sciences [added: Solutions] reporting unit exceeded the carrying value by more than 10% but less than 20%.

The Company determined the fair value of the Life Sciences [added: Solutions] reporting unit using [removed: a combination of] an income approach [removed: and] [added: which was corroborated with] a [removed: discounted cash flow model.][added: market approach.]

The [removed: discounted cash flow model] [added: income approach] required management to make significant estimates and assumptions related to the discount [added: rate and forecasts of future revenue.]

We identified the valuation of the Life Sciences [added: Solutions] reporting unit as a critical audit matter because of the significant estimates and assumptions management made to measure the fair value of the Life Sciences [added: Solutions] reporting unit.

[removed: These fair value measurements] [added: Auditing these estimates and assumptions] required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists, when performing audit procedures to evaluate the reasonableness of management’s [removed: forecasts of future revenue] [added: estimates] and [added: assumptions related to] the selection of the discount rate [removed: for] [added: and revenue growth rates within] the Life Sciences [added: Solutions] reporting unit.

Our audit procedures related to [added: testing] the [removed: forecasts of future revenue and] selection of the discount rate [added: and the forecasts of future revenue] included the following, among others:

–We tested the effectiveness of controls over management’s [added: evaluation of] goodwill [removed: impairment evaluation,] [added: for impairment,] including those controls related to [removed: management’s forecasts and] [added: the] selection of the discount rate [added: and revenue growth rates] used in measuring the fair value of the Life Sciences [added: Solutions] reporting unit.

[removed: –We evaluated] [added: –Evaluated] management’s ability to accurately forecast operating results by comparing actual results to management’s historical forecasts.

[removed: –We evaluated] [added: –Evaluated] the reasonableness of management’s forecasts by comparing the forecasts to (1) historical results, (2) internal communications, budgets and other information obtained while performing the audit and (3) external information.

–We evaluated the discount rate, including testing the underlying source information and [added: mathematical accuracy of the calculations, and] developing a range of independent estimates and comparing those to the discount rate selected by management.

| | | | December [removed: 29, 2024] [added: 28, 2025] | | | | | | December [removed: 31, 2023] [added: 29, 2024] | | | | | | [removed: January 1,] [added: December 31,] 2023 | | |

| Product revenue | | | $ | [removed: 2,338,211] [added: 2,389,984] | | | | | $ | [removed: 2,415,893] [added: 2,338,211] | | | | | $ | [removed: 2,634,582] [added: 2,415,893] | |

| Service revenue | | | [removed: 416,815] [added: 466,067] | | | | | | [removed: 334,678] [added: 416,815] | | | | | | [removed: 677,240] [added: 334,678] | | |

| Total revenue | | | [removed: 2,755,026] [added: 2,856,051] | | | | | | [removed: 2,750,571] [added: 2,755,026] | | | | | | [removed: 3,311,822] [added: 2,750,571] | | |

| Cost of product revenue | | | [removed: 1,041,749] [added: 1,117,132] | | | | | | [removed: 1,077,744] [added: 1,041,749] | | | | | | [removed: 1,150,402] [added: 1,077,744] | | |

| Cost of service revenue | | | [removed: 175,618] [added: 174,554] | | | | | | [removed: 133,136] [added: 175,618] | | | | | | [removed: 171,590] [added: 133,136] | | |

| Selling, general and administrative expenses | | | [removed: 994,074] [added: 991,890] | | | | | | [removed: 1,022,551] [added: 994,074] | | | | | | [removed: 1,025,514] [added: 1,022,551] | | |

| Research and development expenses | | | [removed: 196,844] [added: 215,840] | | | | | | [removed: 216,578] [added: 196,844] | | | | | | [removed: 221,617] [added: 216,578] | | |

| Operating income from continuing operations | | | [removed: 346,741] [added: 356,635] | | | | | | [removed: 300,562] [added: 346,741] | | | | | | [removed: 742,699] [added: 300,562] | | |

| Interest and other expense, net | | | [removed: 30,615] [added: 88,358] | | | | | | [removed: 117,586] [added: 30,615] | | | | | | [removed: 90,862] [added: 117,586] | | |

| Income from continuing operations before income taxes | | | [removed: 316,126] [added: 268,277] | | | | | | [removed: 182,976] [added: 316,126] | | | | | | [removed: 651,837] [added: 182,976] | | |

| Provision for income taxes | | | [added: $ |] 33,055 | | | | | [added: $] | 3,473 | | | | | | [removed: 139,161] | | [removed: |]

| Income from continuing operations | | | [removed: 283,071] [added: 239,883] | | | | | | [removed: 179,503] [added: 283,071] | | | | | | [removed: 512,676] [added: 179,503] | | |

| [removed: (Loss) income] [added: Income (loss)] from discontinued operations | | | [removed: (12,686)] [added: 1,318] | | | | | | [removed: 513,591] [added: (12,686)] | | | | | | [removed: 56,503] [added: 513,591] | | |

| Net income | | | $ | [removed: 270,385] [added: 241,201] | | | | | $ | [removed: 693,094] [added: 270,385] | | | | | $ | [removed: 569,179] [added: 693,094] | |

| Income from continuing operations | | | $ | [removed: 2.31] [added: 2.06] | | | | | $ | [removed: 1.44] [added: 2.31] | | | | | $ | [removed: 4.06] [added: 1.44] | |

| [removed: (Loss) income] [added: Income (loss)] from discontinued operations | | | [removed: (0.10)] [added: 0.01] | | | | | | [removed: 4.12] [added: (0.10)] | | | | | | [removed: 0.45] [added: 4.12] | | |

February 24, 2026

| Provision for income taxes | | | 28,394 | | | | | | 33,055 | | | | | | 3,473 | | |

| | | | December 28, 2025 | | | | | | December 29, 2024 | | |

| Net income | | | — | | | | | | — | | | | | | — | | | | | | 241,201 | | | | | | — | | | | | | 241,201 | | |

| Purchases of common stock | | | (8,546) | | | | | | (8,546) | | | | | | (819,510) | | | | | | — | | | | | | — | | | | | | (828,056) | | |

| Balance, December 28, 2025 | | | 112,281 | | | | | | $ | 112,281 | | | | | $ | 1,305,900 | | | | | $ | 6,054,314 | | | | | $ | (222,135) | | | | | $ | 7,250,360 | |

| Net income | | | $ | 241,201 | | | | | $ | 270,385 | | | | | $ | 693,094 | |

The tax benefit recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement.

ROU assets represent the Company’s right to use an

In December 2025, the FASB issued Accounting Standards Update 2025-10, *Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities* (“ASU 2025-10”), which establishes authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants.

Under ASU 2025-10, government grants are recognized when it is probable that the entity will both comply with the conditions of the grant and the grant will be received.

ASU 2025-10 provides specific accounting models for grants related to assets and grants related to income, including options to recognize government grants as deferred income or as a reduction of the asset’s cost basis.

ASU 2025-10 also requires enhanced disclosures regarding the nature of government grants, significant terms and conditions, accounting policies applied, and amounts recognized in the financial statements.

ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years, with early adoption permitted.

The Company is currently evaluating the impact of adopting ASU 2025-10 but does not expect the impact of such adoption to be material.

In December 2025, the FASB issued Accounting Standards Update 2025-11, *Interim Reporting (Topic 270): Narrow-Scope Improvements* (“ASU 2025-11”), which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting.

ASU 2025-11 provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity.

ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted.

The Company is currently evaluating the impact of adopting ASU 2025-11.

In September 2025, the FASB issued Accounting Standards Update 2025-06, *Targeted Improvements to the Accounting for Internal-Use Software* (“ASU 2025-06”).

ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs.

The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods.

Early adoption is permitted as of the beginning of an annual reporting period.

The guidance may be applied prospectively, retrospectively, or via a modified prospective transition method.

In addition, ASU 2024-03 requires public

The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.

| Americas | | | $ | 750,857 | | | | | $ | 505,104 | | | | | $ | 1,255,961 | | | | | $ | 745,206 | | | | | $ | 477,881 | | | | | $ | 1,223,087 | | | | | $ | 759,782 | | | | | $ | 455,831 | | | | | $ | 1,215,613 | |

| Europe | | | 343,507 | | | | | | 481,471 | | | | | | 824,978 | | | | | | 315,173 | | | | | | 427,441 | | | | | | 742,614 | | | | | | 344,713 | | | | | | 402,310 | | | | | | 747,023 | | |

| Asia | | | 336,740 | | | | | | 438,372 | | | | | | 775,112 | | | | | | 338,222 | | | | | | 451,103 | | | | | | 789,325 | | | | | | 353,697 | | | | | | 434,238 | | | | | | 787,935 | | |

| | | | $ | 1,431,104 | | | | | $ | 1,424,947 | | | | | $ | 2,856,051 | | | | | $ | 1,398,601 | | | | | $ | 1,356,425 | | | | | $ | 2,755,026 | | | | | $ | 1,458,192 | | | | | $ | 1,292,379 | | | | | $ | 2,750,571 | |

| Life Sciences Solutions | | | $ | 1,194,728 | | | | | $ | — | | | | | $ | 1,194,728 | | | | | $ | 1,197,802 | | | | | $ | — | | | | | $ | 1,197,802 | | | | | $ | 1,279,903 | | | | | $ | — | | | | | $ | 1,279,903 | |

| Immunodiagnostics | | | — | | | | | | 869,908 | | | | | | 869,908 | | | | | | — | | | | | | 828,627 | | | | | | 828,627 | | | | | | — | | | | | | 787,394 | | | | | | 787,394 | | |

| Reproductive health | | | — | | | | | | 555,039 | | | | | | 555,039 | | | | | | — | | | | | | 527,798 | | | | | | 527,798 | | | | | | — | | | | | | 504,985 | | | | | | 504,985 | | |

| | | | $ | 1,431,104 | | | | | $ | 1,424,947 | | | | | $ | 2,856,051 | | | | | $ | 1,398,601 | | | | | $ | 1,356,425 | | | | | $ | 2,755,026 | | | | | $ | 1,458,192 | | | | | $ | 1,292,379 | | | | | $ | 2,750,571 | |

The capital expenditures from discontinued operations for the fiscal year 2023 were not material.

Note 4: Restructuring and Other Costs

Restructuring and other costs in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Company’s workforce.

Restructuring and other costs in fiscal years 2024 and 2023 primarily included charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

Severance actions associated with facility consolidations and cost reduction initiatives were not material to the Company’s overall workforce in both fiscal years.

rate and forecasts of future revenue.

February 25, 2025

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Unrecognized prior service credit, net of tax | | | — | | | | | | — | | | | | | 44 | | |

| Marketable securities | | | — | | | | | | 689,916 | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Balance, January 2, 2022 | | | 126,241 | | | | | | $ | 126,241 | | | | | $ | 2,760,522 | | | | | $ | 4,417,174 | | | | | $ | (162,692) | | | | | $ | 7,141,245 | |

| Net income | | | — | | | | | | — | | | | | | — | | | | | | 569,179 | | | | | | — | | | | | | 569,179 | | |

| Purchases of common stock | | | (493) | | | | | | (493) | | | | | | (80,145) | | | | | | — | | | | | | — | | | | | | (80,638) | | |

| Gain on disposition of businesses and assets, net | | | — | | | | | | — | | | | | | (2,887) | | |

| Amortization of acquired inventory revaluation | | | — | | | | | | — | | | | | | 45,289 | | |

| Proceeds from disposition of businesses and assets | | | — | | | | | | 153 | | | | | | 14,505 | | |

| Payments on borrowings | | | — | | | | | | — | | | | | | (740,000) | | |

| Proceeds from borrowings | | | — | | | | | | — | | | | | | 240,000 | | |

| Settlement of cash flow hedges | | | — | | | | | | — | | | | | | (762) | | |

| Cash and cash equivalents included in current assets of discontinued operations | | | — | | | | | | — | | | | | | 14,999 | | |

| Income taxes | | | 154,876 | | | | | | 359,800 | | | | | | 323,077 | | |

The Company changed the measurement date to more closely align the annual impairment testing date with the most current information from the budgeting and strategic planning process.

The Company believes the change in goodwill impairment testing date does not represent a material change to the Company’s method of applying an accounting principle in light of the Company’s internal controls and requirements to assess goodwill impairment upon certain triggering events.

This change was applied prospectively and

therefore, the Company performed its annual impairment testing for its reporting units for fiscal year 2024 as of January 1, 2024 and November 1, 2024.

The Company concluded that there was no goodwill impairment in the periods presented.

The Company recorded restructuring charges, included in selling, general and administrative expenses in the consolidated statements of operations, of $17.5 million, $26.6 million and $13.6 million primarily associated with workforce reductions during fiscal years 2024, 2023 and 2022, respectively.

The Company expects severance payments will be substantially completed during fiscal year 2025.

as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings.

Early adoption is permitted.

The guidance is required to be applied on a prospective basis; retrospective application is permitted.

effective for annual periods beginning after December 15, 2024.

The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.

In November 2023, the FASB issued Accounting Standards Update 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* (“ASU 2023-07”).

ASU 2023-07 amends Accounting Standards Codification 280, *Segment Reporting* (“ASC 280”) to require public entities to disclose significant segment expenses and other segment items that are regularly provided to the chief operating decision maker (“CODM”) and included in each reported measure of a reportable segment’s profit or loss, on an annual and interim basis, and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually.

ASU 2023-07 permits entities to report multiple measures of a reportable segment’s profit or loss if the CODM uses those measures to allocate resources and assess performance.

| Americas | | | $ | 659,444 | | | | | $ | 563,642 | | | | | $ | 1,223,086 | | | | | $ | 671,738 | | | | | $ | 543,875 | | | | | $ | 1,215,613 | | | | | $ | 683,170 | | | | | $ | 979,473 | | | | | $ | 1,662,643 | |

| Europe | | | 283,256 | | | | | | 459,358 | | | | | | 742,614 | | | | | | 308,567 | | | | | | 438,457 | | | | | | 747,024 | | | | | | 297,468 | | | | | | 534,343 | | | | | | 831,811 | | |

| Asia | | | 311,445 | | | | | | 477,881 | | | | | | 789,326 | | | | | | 312,035 | | | | | | 475,899 | | | | | | 787,934 | | | | | | 312,271 | | | | | | 505,097 | | | | | | 817,368 | | |

| | | | $ | 1,254,145 | | | | | $ | 1,500,881 | | | | | $ | 2,755,026 | | | | | $ | 1,292,340 | | | | | $ | 1,458,231 | | | | | $ | 2,750,571 | | | | | $ | 1,292,909 | | | | | $ | 2,018,913 | | | | | $ | 3,311,822 | |

| Life Sciences reagents | | | $ | 719,268 | | | | | $ | — | | | | | $ | 719,268 | | | | | $ | 732,789 | | | | | $ | — | | | | | $ | 732,789 | | | | | $ | 691,344 | | | | | $ | — | | | | | $ | 691,344 | |

| Life Sciences instruments | | | 334,078 | | | | | | — | | | | | | 334,078 | | | | | | 381,262 | | | | | | — | | | | | | 381,262 | | | | | | 405,554 | | | | | | — | | | | | | 405,554 | | |

| Reproductive health | | | — | | | | | | 523,931 | | | | | | 523,931 | | | | | | — | | | | | | 501,302 | | | | | | 501,302 | | | | | | — | | | | | | 516,574 | | | | | | 516,574 | | |

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December [removed: 29, 2024.][added: 28, 2025.]

Based on the evaluation of our disclosure controls and procedures as of December [removed: 29, 2024,] [added: 28, 2025,] our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

[added: Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a] process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

Our management assessed the effectiveness of our internal control over financial reporting as of December [removed: 29, 2024.][added: 28, 2025.]

Based on this assessment, our management concluded that, as of December [removed: 29, 2024,] [added: 28, 2025,] our internal control over financial reporting was effective based on those criteria.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December [removed: 29, 2024] [added: 28, 2025] that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We have audited the internal control over financial reporting of Revvity, Inc. and subsidiaries (the “Company”) as of December [removed: 29, 2024,] [added: 28, 2025,] based on criteria established in *Internal Control—Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December [removed: 29, 2024,] [added: 28, 2025,] based on criteria established in *Internal Control – Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December [removed: 29, 2024,] [added: 28, 2025,] of the Company and our report dated February [removed: 25, 2025,] [added: 24, 2026,] expressed an unqualified opinion on those financial statements.

We believe that our audit [added: provides a reasonable basis for our opinion.]

February 24, 2026

Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a

provides a reasonable basis for our opinion.

February 25, 2025

During the three months ended December [removed: 29, 2024,] [added: 28, 2025,] none of our directors or [removed: officers] [added: officers, for purposes of Section 16 of the Securities Exchange Act of 1934,] adopted a [removed: “Rule 10b5-1 trading arrangement” or] “non-Rule 10b5-1 trading arrangement”, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as the terms are defined in Item 408(a) of Regulation S-K.

During the three months ended December 28, 2025, Anita Gonzales and Miriame Victor, each an officer for purposes of

Section 16 of the Securities Exchange Act of 1934, adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K.

| | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | Rule 10b5-1 Trading Arrangements | | | | | | | | | | | | | | | | | | | | |

| Name | | | | | | Position | | | | | | Trading Arrangement Adoption Date | | | | | | Duration of Trading Arrangement | | | | | | Aggregate Number of Securities to be Sold under the Trading Arrangement | | |

| Anita Gonzales | | | | | | Vice President and Chief Accounting Officer | | | | | | November 7, 2025 | | | | | | April 20, 2026 - November 6, 2026 | | | | | | Up to 249 | | |

| Miriame Victor | | | | | | Senior Vice President, Chief Commercial Officer | | | | | | November 26, 2025 | | | | | | February 24, 2026 - March 2, 2026 | | | | | | Up to 1,862 | | |

[added: The remaining information required to be disclosed by the] Item [added: pursuant to Item 401, Item 405, Item] 407 and Item 408(b) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the captions “Proposal No. 1 Election of Directors”, “Delinquent Section 16(a) Reports” and “Information Relating to Our Board of Directors and Its Committees” and is incorporated in this annual report on Form 10-K by reference.

The remaining information required to be disclosed by the Item pursuant to Item 401, Item 405.

The information required to be disclosed by this Item pursuant to Item 402 and Item 407(e) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the captions “Director Compensation,” “Information Relating to Our Board of Directors and Its Committees—Compensation Committee Interlocks and Insider Participation,” and “Executive Compensation,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 403 of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the caption “Beneficial Ownership of Common Stock,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 201(d) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the caption “Executive Compensation—Equity Compensation Plan Information,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 404 of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the caption “Information Relating to Our Board of Directors and Its Committees—Certain Relationships and Policies on Related Party Transactions,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 407(a) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the caption “Information Relating to Our Board of Directors and Its Committees—Determination of Independence,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 9(e) of Schedule 14A is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 22, 2025] [added: 28, 2026] under the caption “Information Relating to Our Board of Directors and Its Committees—Independent Registered Public Accounting Firm Fees and Other Matters”, and is incorporated in this annual report on Form 10-K by reference.

Consolidated Statements of Operations for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024][added: 28, 2025]

Consolidated Statements of Comprehensive Income for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024][added: 28, 2025]

Consolidated Balance Sheets as of December [removed: 29, 2024] [added: 28, 2025] and December [removed: 31, 2023][added: 29, 2024]

Consolidated Statements of Stockholders’ Equity for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024][added: 28, 2025]

Consolidated Statements of Cash Flows for Each of the Three Fiscal Years in the Period Ended December [removed: 29, 2024][added: 28, 2025]

| 3.1 | | | | | | [Revvity, Inc.'s Restated Articles of Organization, as amended, filed with the Commission on [removed: November] [added: May] 6, [removed: 2024] [added: 2025] as Exhibit 3.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000028/q3-202410qexhibit31.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000015/q1-202510qexhibits31.htm)] | | | | | | | | | | | |

| 3.2 | | | | | | [Revvity, Inc.'s Amended and Restated By-laws, filed with the Commission on May [removed: 12, 2023] [added: 6, 2025] as Exhibit 3.2 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000031791/000003179123000008/pki-20230402.htm#ib655ed8501a2415ba17d414b86275250_160)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000015/q1-202510qexhibits32.htm)] | | | | | | | | | | | |

| [removed: 4.2] [added: 19] | | | | | | [removed: [Description of Revvity, Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act] [added: [Securities Trading Policy dated as] of [removed: 1934,] [added: February 11, 2025,] filed with the Commission on [removed: March 3, 2022] [added: February 25, 2025] as Exhibit [removed: 4.2] [added: 19] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit42.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a2024exhibit19.htm)] | | | | | | | | | | | |

| 10.25* | | | | | | [Form of [removed: Restricted] Stock [added: Option] Agreement with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on [removed: May 11, 2021] [added: February 27, 2024] as Exhibit [removed: 10.3] [added: 10.27] to our [removed: quarterly] [added: annual] report on Form [removed: 10-Q] [added: 10-K] (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179121000006/q1-2021exhibit103.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1027.htm)] | | | | | | | | | | | |

| 10.26* | | | | | | [Form of [removed: Restricted] Stock [added: Option] Agreement with double-trigger vesting acceleration [removed: upon] [added: following] a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on [removed: May 11, 2021] [added: February 27, 2024] as Exhibit [removed: 10.4] [added: 10.28] to our [removed: quarterly] [added: annual] report on Form [removed: 10-Q] [added: 10-K] (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179121000006/q1-2021exhibit104.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1028.htm)] | | | | | | | | | | | |

| 10.27* | | | | | | [Form of [added: Restricted] Stock [removed: Option] [added: Unit] Agreement [added: (Performance-based vesting)] with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit [removed: 10.27] [added: 10.29] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1027.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1029.htm)] | | | | | | | | | | | |

| 10.28* | | | | | | [Form of [added: Restricted] Stock [removed: Option] [added: Unit] Agreement [added: (Performance-based vesting)] with double-trigger vesting acceleration [removed: following] [added: upon] a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit [removed: 10.28] [added: 10.30] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1028.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1030.htm)] | | | | | | | | | | | |

| 10.29* | | | | | | [Form of Restricted Stock Unit Agreement [removed: (Performance-based] [added: (Time-based] vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit [removed: 10.29] [added: 10.31] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1029.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1031.htm)] | | | | | | | | | | | |

| 10.30* | | | | | | [Form of Restricted Stock Unit Agreement [removed: (Performance-based] [added: (Time-based] vesting) with double-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit [removed: 10.30] [added: 10.32] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1030.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1032.htm)] | | | | | | | | | | | |

| 21 | | | | | | [Subsidiaries of Revvity, Inc., attached hereto as Exhibit [removed: 21.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a2024exhibit21.htm)] [added: 21.](https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/a2025exhibit21.htm)] | | | | | | | | | | | |

| 23 | | | | | | [Consent of Independent Registered Public Accounting Firm, attached hereto as Exhibit [removed: 23.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a2024exhibit23.htm)] [added: 23.](https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/a2025exhibit23.htm)] | | | | | | | | | | | |

| 31.1 | | | | | | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, attached hereto as Exhibit [removed: 31.1.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a202410kcert-ex_311.htm)] [added: 31.1.](https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/a202510kcert-ex_311.htm)] | | | | | | | | | | | |

| 31.2 | | | | | | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, attached hereto as Exhibit [removed: 31.2.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a202410kcert-ex_312.htm)] [added: 31.2.](https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/a202510kcert-ex_312.htm)] | | | | | | | | | | | |

| 32.1 | | | | | | [Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, attached hereto as Exhibit [removed: 32.1.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a202410kcert-ex_321.htm)] [added: 32.1.](https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/a202510kcert-ex_321.htm)] | | | | | | | | | | | |

(i) Consolidated Statements of Operations for each of the three years in the period ended December [removed: 29, 2024,] [added: 28, 2025,] (ii) Consolidated Balance Sheets as of December [removed: 29, 2024] [added: 28, 2025] and December [removed: 31, 2023,] [added: 29, 2024,] (iii) Consolidated Statements of Comprehensive Income for each of the three years in the period ended December [removed: 29, 2024,] [added: 28, 2025,] (iv) Consolidated Statements of Stockholders' Equity for each of the three years in the period ended December [removed: 29, 2024,] [added: 28, 2025,] (v) Consolidated Statements of Cash Flows for each of the three years in the period ended December [removed: 29, 2024,] [added: 28, 2025,] and (vi) Notes to Consolidated Financial Statements.

| 4.2 | | | | | | [Description of Revvity, Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, attached hereto as Exhibit 4.2.](https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/exhibit42.htm) | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | |

| 10.31* | | | | | | [Form of Restricted Stock Unit Agreement (Time-based vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit 10.31 to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1031.htm) | | | | | | | | | | | |

| 10.32* | | | | | | [Form of Restricted Stock Unit Agreement (Time-based vesting) with double-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit 10.32 to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/a2023exhibit1032.htm) | | | | | | | | | | | |

| 19 | | | | | | [Securities Trading Policy dated as of February 11, 2025, attached hereto as Exhibit 19.](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/a2024exhibit19.htm) | | | | | | | | | | | |

| By: | | | /s/ PRAHLAD SINGH, PhD | | | | | | President and Chief Executive Officer | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ MAXWELL KRAKOWIAK | | | | | | Sr. Vice President and Chief Financial Officer | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ ANITA GONZALES | | | | | | Vice President and [removed: Controller] | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| | | | Anita Gonzales | | | | | | [added: Chief Accounting Officer] (Principal Accounting Officer) | | | | | | | | |

| By: | | | /s/ PRAHLAD SINGH, PhD | | | | | | President, Chief Executive Officer and | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ MAXWELL KRAKOWIAK | | | | | | Sr. Vice President and | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ PETER BARRETT, PhD | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ SAMUEL R. CHAPIN | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ MICHAEL A. KLOBUCHAR | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ MICHELLE MCMURRY-HEATH, MD PhD | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ ALEXIS P. MICHAS | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s SOPHIE V. VANDEBROEK, PhD | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ MICHEL VOUNATSOS | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ FRANK WITNEY, PhD | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ PASCALE WITZ | | | | | | Director | | | | | | February [removed: 25, 2025] [added: 24, 2026] | | |

| By: | | | /s/ ANITA GONZALES | | | | | | Vice President and Chief Accounting Officer | | | | | | February 24, 2026 | | |